Qiagen (QGEN) Leerink Global Healthcare Conference 2026 summary

Strategic review and leadership transition

• Ongoing CEO search is progressing well, with an announcement expected in Q2 2024.

• Board and management are open to strategic alternatives, including M&A and potential combinations with larger companies.

• Recent acquisitions like Genoox and Parse have built a strong track record for value creation.

• Shareholder value remains a key focus during this transition period.

Market conditions and macroeconomic impacts

• Logistics disruptions and inflationary pressures are being monitored, but most freight costs are passed to customers, minimizing net impact.

• Funding for academic and pharma sectors remains stable, with U.S. NIH budget growing 1%.

• Instrumentation sales are more sensitive to confidence and long-term funding outlooks, especially in the U.S.

• European and clinical markets show more stability compared to U.S. academics.

Revenue guidance and growth drivers

• Organic growth guidance is 1% for Q1 and 5% for the full year, with a significant ramp expected in H2.

• Discontinuation of NeuMoDx and Dialunox will reduce headwinds by mid-year, contributing 200 basis points to H2 growth.

• New product launches, including three sample prep machines, are expected to add $15 million in H2.

• Parse acquisition is projected to accelerate, with revenues expected to exceed $40 million in 2026.

• QuantiFERON growth normalizes after strong prior-year tenders, with a revised CAGR of around 7%.